<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="83967">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01895049</url>
  </required_header>
  <id_info>
    <org_study_id>CRAD001ABR32T</org_study_id>
    <nct_id>NCT01895049</nct_id>
  </id_info>
  <brief_title>Comparison Between Two Tacrolimus-based Immunosuppressant Regimens and Induction With Thymoglobulin in Kidney Transplants From Deceased Donors With Expanded Criteria</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Helio Tedesco Silva Junior</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Hospital do Rim e Hipertensão</source>
  <oversight_info>
    <authority>Brazil:ANVISA</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The disparity between supply and demand for organs has stimulated the development of
      strategies to increase the availability of kidney grafts. Such strategy involves the use of
      kidneys with expanded donor criteria (EDC). This is a study initiated by the investigator,
      open, prospective, randomized, single center designed to compare the safety and efficacy of
      two immunosuppressive regimens based on thymoglobulin, tacrolimus and everolimus versus
      thymoglobulin, tacrolimus and mycophenolate sodium in renal transplant recipients with donor
      criteria expanded.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>August 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">July 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Incidence of CMV disease</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence of CMV disease or infection during the first year of transplantation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>incidence of treatment failure</measure>
    <time_frame>1 year</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the two immunosuppressive regimens for the incidence of treatment failure defined as the composite endpoint of BPAR (biopsy-proven acute rejection), graft loss, death and loss to follow-up.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Kidney Transplantation</condition>
  <condition>Cytomegalovirus</condition>
  <arm_group>
    <arm_group_label>Mycophenolate sodium</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium, and late introduction of tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Everolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Induction therapy with Thymoglobulin, prednisone, everolimus, and late introduction of tacrolimus.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus</intervention_name>
    <arm_group_label>Everolimus</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus</intervention_name>
    <arm_group_label>Mycophenolate sodium</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults (&gt; 18 years) candidates to renal transplant with expanded criteria deceased
             donors;

          -  Low risk of acute rejection, defined as first kidney transplant recipients and Panel
             Reactive Antibody (PRA) &lt;50%.

          -  Signature of the informed consent form (ICF)

        Exclusion Criteria:

          -  Patients receiving immunosuppressive therapy before transplantation;

          -  Patients who have received an investigational drug within last 30 days;

          -  Patients with a known contraindication to the administration of an anti-thymocyte
             globulin;

          -  Patients with a positive test for human immunodeficiency virus (HIV);

          -  Patients who had cancer (except non-melanoma skin cancer) within last two years;

          -  Pregnant women, breastfeeding women, and women of childbearing potential unwilling to
             use condoms or oral contraceptives will be excluded;

          -  Patients with any Panel Reactive Antibody (PRA) equal to or higher than 50%, class I
             or class II, will also be excluded;

          -  Patients with positive test for parasites (protozoa and helminths).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Helio Tedesco, PhD</last_name>
    <phone>55-11-5087-8113</phone>
    <email>heliotedesco@hrim.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Claudia R Felipe, PhD</last_name>
    <phone>55-11-5087-8113</phone>
    <email>claudiafelipe@medfarm.com.br</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital do Rim e Hipertensao</name>
      <address>
        <city>São Paulo</city>
        <zip>04038-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claudia R Felipe, PhD</last_name>
      <phone>55 11 5087-8113</phone>
      <email>claudiafelipe@medfarm.com.br</email>
    </contact>
    <contact_backup>
      <last_name>Nagilla I Oliveira, Master</last_name>
      <phone>55-11-5087-8113</phone>
      <email>nagilla.oliveira@medfarm.com.br</email>
    </contact_backup>
    <investigator>
      <last_name>Helio Tedesco, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Brazil</country>
  </location_countries>
  <verification_date>July 2013</verification_date>
  <lastchanged_date>July 4, 2013</lastchanged_date>
  <firstreceived_date>July 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Hospital do Rim e Hipertensão</investigator_affiliation>
    <investigator_full_name>Helio Tedesco Silva Junior</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>Tacrolimus</keyword>
  <keyword>Everolimus</keyword>
  <keyword>Cytomegalovirus</keyword>
  <keyword>Thymoglobulin</keyword>
  <keyword>Deceased donors</keyword>
  <keyword>Expanded criteria</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Immunosuppressive Agents</mesh_term>
    <mesh_term>Mycophenolate mofetil</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
